secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2023-01-05T23:59:59+00:00
Accession:  0000950170-23-000230
Event type: leadership
Sentiment:  positive
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista promotes CFO/CBO Palleiko to President; cites $190M cash for sebetralstat launch prep
--------------------------------------------------------------------------------

- Benjamin L. Palleiko appointed President effective Jan 4, 2023, while retaining CFO and CBO roles.
- Promotion follows $58M registered direct offering in Dec 2022 at 17% premium; pro forma cash ~$190M.
- Palleiko to lead commercial organization for planned launch of sebetralstat, an oral HAE therapy in Phase 3.
- KalVista expects KONFIDENT Phase 3 data in H2 2023 and NDA filing in H1 2024; cash runway into 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000095017023000230/0000950170-23-000230-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000095017023000230/kalv-20230104.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-000230

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer